Lanean...
Immunotherapy for metastatic prostate cancer
Chemotherapy with docetaxel is the standard treatment for men with metastatic prostate cancer, and results in statistically significant improvements in survival, as well as in quality of life. However, the response rate to single-agent docetaxel is approximately 40% to 45%, emphasizing a need for al...
Gorde:
| Argitaratua izan da: | Urol Oncol |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2007
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4886229/ https://ncbi.nlm.nih.gov/pubmed/18593624 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2007.03.029 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|